Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 48

Results For "Mila"

534 News Found

Medical institutes urge action on Front-of-Pack labels (FOPL) to address India’s health crisis
Public Health | September 14, 2021

Medical institutes urge action on Front-of-Pack labels (FOPL) to address India’s health crisis

Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor


Navitas Life Sciences acquires its 200th customer
Digitisation | September 08, 2021

Navitas Life Sciences acquires its 200th customer

First launched in 2005, pharmaREADY is a fully integrated, regulatory compliant, web-based platform to create, view, and manage global regulatory submissions


HUL funds study on Covid-19 vulnerability and vaccine efficiency
News | September 07, 2021

HUL funds study on Covid-19 vulnerability and vaccine efficiency

The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.


DGCI approves Hetero’s Tocilizumab
Drug Approval | September 06, 2021

DGCI approves Hetero’s Tocilizumab

Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month


Accutest enables NMPA approval for Qilu’s Abiraterone
Drug Approval | September 06, 2021

Accutest enables NMPA approval for Qilu’s Abiraterone

The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India


HCG acquires oncology labs and divests stake in Strand Life Sciences
Healthcare | September 04, 2021

HCG acquires oncology labs and divests stake in Strand Life Sciences

The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business


Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab
Drug Approval | September 01, 2021

Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab

JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis


Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis
Biotech | August 31, 2021

Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis

Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old


Acute therapies drive overall pharma growth in July: Ind-Ra
News | August 30, 2021

Acute therapies drive overall pharma growth in July: Ind-Ra

The segment delivered strong sales growth of 20% YoY


Covid-19 infected individuals need only one dose of Covaxin: ICMR study
News | August 28, 2021

Covid-19 infected individuals need only one dose of Covaxin: ICMR study

Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021